Tate & Lyle PLC - Proposed acquisition of The Minority Interests in Amylum and Staley

| Filed in:
Tate & Lyle PLC ("Tate & Lyle" or the "Group") announces that it has reached agreement with Compagnie Industrielle et Financière des Produits Amylaces S.A. ("CIP") to acquire, for a total consideration of £274 million, the minority interests held by CIP in Amylum (36.7 per cent) and Staley (10.0 per cent), Tate & Lyle’s European and US starch subsidiaries.

On completion, Tate & Lyle will own 100 per cent of Amylum and Staley.

The consideration will be satisfied by the payment to CIP of £210 million in cash, with the balance satisfied by the issuance of 24.08 million new Tate & Lyle shares (the "Consideration Shares"). The Consideration Shares will be issued credited as fully paid, and will rank pari passu in all respects with Tate & Lyle’s existing ordinary shares, except that they will not rank for the final dividend in respect of the 18 months ended 25 March 2000, to be paid on 2 August 2000.

It is expected that, in the first full year of ownership, the transaction will have a positive return over the cost of capital before goodwill amortisation, and enhance earnings per share.

The acquisition of the minority interests in Amylum and Staley is conditional on EU merger approval, and listing of the Consideration Shares in the Official List and their admission to trading by the London Stock Exchange.

On completion, Amylum will be integrated with other Group businesses. Frank Karsbergen will continue as Chief Executive of Amylum reporting to Tate & Lyle Chief Executive, Larry Pillard, who will also be Chairman of Amylum.

On completion, Carole Piwnica will remain a non-executive director of Tate & Lyle and will also become Non-Executive Vice-Chairman – Government Affairs for Tate & Lyle. On completion, she will enter into a three year consultancy agreement with the Group.

Commenting on the proposed acquisition, Larry Pillard, Chief Executive of Tate & Lyle said:

"We expect to derive significant efficiencies over time from the integration of the Amylum business into the Tate & Lyle Group, beginning in the first full year of operation.

"This acquisition, together with the disposal of Bundaberg, marks a clear strategic step for the Tate & Lyle Group, enabling us to focus on the development of the combined businesses of Amylum and Staley as leading value added processors of carbohydrates. Both Amylum and Staley are world-class businesses, with complementary skills, technologies and markets. We will now be able to achieve full transfer of these skills and technologies and create an integrated approach to product development and marketing.

"This approach offers powerful prospects for better servicing the requirements of our customers around the world and increasing the already significant contribution of value-added products within the Tate & Lyle Group.

"I am delighted that Carole Piwnica has agreed to remain a non-executive director of Tate & Lyle and I am confident she will make a major contribution in her new role assisting us with our government relations activities.

"I look forward, both as Tate & Lyle Chief Executive and Chairman of Amylum, to taking the combined businesses forward and realising their full potential."

Expected benefits from the proposed acquisition
The full integration of Amylum into the Tate & Lyle Group will give rise to widespread savings and efficiencies and product development opportunities. These include:

  • Organisation enhancement: Organisation between Amylum and the rest of the Tate & Lyle Group will be optimised in many areas, including: IT, sales and marketing, purchasing, supply chain, finance and administration, operations and engineering, and human resources. This will also reduce costs.

  • Improved efficiencies: Tate & Lyle believes that there will be significant scope to improve efficiency through applying best practices from both businesses in the enlarged Tate & Lyle Group.

  • Sales and marketing: The Tate & Lyle Group will be better positioned to serve an increasingly global customer base. The integration of the two cereal sweeteners and starch businesses will give rise to enhanced cross selling and export opportunities and greater efficiency in servicing export markets.

  • Research and development: The current ownership structure of Amylum has limited the full transfer of product and process technology between Tate & Lyle and Amylum. The proposed acquisition will enable Tate & Lyle to integrate its research and development capabilities and leverage the respective expertise of Tate & Lyle and Amylum on a global basis. This will greatly enhance development opportunities, particularly in value added products, and facilitate production cost savings across the Group.


The cash consideration for the proposed acquisition will be funded from Tate & Lyle’s existing banking facilities.

Information on Amylum and Staley

Amylum is one of the leading producers of cereal sweeteners and starches in Europe. Its principal operations are in France, Belgium, the UK, Spain, Holland, Italy and Greece. It is also a leading manufacturer of sweetener products in Eastern Europe through its Eaststarch joint venture.

Staley is one of the top three corn wet millers in the US. The integration as a product line within Staley of the global citric acid business, Tate & Lyle Citric Acid, which was acquired from Bayer in 1998, has added significant capability in value added fermentation to Staley’s technology portfolio.

In the 12 months to 25 March 2000, the combined unaudited profit before tax attributable to the minorities in Amylum and Staley was £21 million. The combined unaudited net assets attributable to the minorities to be purchased in Amylum and Staley at 25 March 2000 were £123 million.

Information on CIP

CIP is a private investment group based in Luxembourg.

It started to invest in starch and products derived from starch in the previous century. Its main investments are in Amylum and Staley.
Tate & Lyle is a global leader in carbohydrate processing. Its principal operations are in Europe and the US. Its brands and high quality ingredients add value to consumer products around the world. Amylum is one of three leading producers of cereal sweeteners and starches in Europe. Amylum is also a leading manufacturer of sweetener products in Eastern Europe through its Eaststarch joint venture. Staley is one of the top three corn wet millers in the US. CIP’s current direct and indirect ownership of Amylum and Staley is 36.7 per cent and 10.0 per cent respectively. On completion of the proposed acquisitions, Tate & Lyle will have 100 per cent ownership of Amylum and Staley while CIP will be issued with a 5.0 per cent holding in Tate & Lyle. Tate & Lyle’s investment in Amylum dates from 1976, when it acquired a 33.3 per cent interest in the business, making it an equal partner with CIP and Staley. With Tate & Lyle’s acquisition of Staley in 1988, Tate & Lyle became the majority shareholder in Amylum with an additional 33.3 per cent owned through Staley.

Click here for our press image gallery

About Tate & Lyle: 
Supported by our 160-year history of ingredient innovation, we partner with customers to provide consumers with healthier and tastier choices when they eat and drink. We are proud that millions of people around the world consume products containing our ingredients every day.

Through our expertise in sweetening, fortification, and texture, we develop ingredient solutions which reduce sugar, calories, and fat, add fibre and protein, and provide texture and stability in categories including beverages, dairy, bakery, snacks, soups, sauces, and dressings.

We have more than 3,500 employees working in around 57 locations across 39 countries. Science, Solutions, Society is our brand promise and how we will achieve our purpose of Transforming Lives Through the Science of Food. By living our purpose we believe we can successfully grow our business and have a positive impact on society. We live our purpose in three ways, by supporting healthy living, building thriving communities and caring for our planet.

Tate & Lyle is listed on the London Stock Exchange under the symbol TATE.L. American Depositary Receipts trade under TATYY. In the year to 31 March 2023, Tate & Lyle revenue from continuing operations totalled £1.75 billion. For more information, please visit https://www.tateandlyle.com or follow Tate & Lyle on TwitterLinkedinFacebook or YouTube